



wherein: X is a linker selected from the group consisting of  $C_1$ - $C_6$  alkylene,  $C_2$ - $C_6$  alkenylene, or  $C_3$ - $C_6$  alkynylene, wherein X may optionally include 1 or 2 oxygen atoms and/or 1 sulfur atom;

Y is a group pendant from X, wherein Y is a  $C_1$ - $C_{10}$  alkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_2$ - $C_{10}$  alkynyl, aromatic or cyclic-aliphatic group to which is attached at least one  $-OSO_3R^4$  moiety, and, optionally, at least one OH group, wherein  $R^4$  is H or a pharmaceutically acceptable cation; or,

Y is  $-OSO_3R^4$ , wherein  $R^4$  is H or a pharmaceutically acceptable cation;

N is an integer from 1-3; and

$R^1$  and  $R^2$  are each independently selected from the group consisting of -H, a halogen with an atomic number from 9 to 53, hydroxy,  $-SO_3R^4$ ,  $-OSO_3R^4$ , -NCS, -NCO,  $-NH(CO)-OR^3$ ,  $-NH(CS)SR^3$ ,  $-NH(C=NH)OR^3$ ,  $-NHCOCH_2Cl$ ,  $-NHCOCH_2Br$ ,  $-NHCO-CH=CH_2$ ,  $-NHC(O)-CF_3$ ,  $-S-CH_2-CH=CH_2$ ,  $-NHCH_2-C\equiv CH$ ,  $-NH-CH_2-CN$ ,  $-NH-S-CH_2-CH=CH_2$ ,  $-O-CH_2-CH=CH_2$ ,  $-NH-CF_3$ , N-mono-, di-, tri-, tetra- and penta-haloethyl, -CN,  $-NH_2$ ,  $-NO_2$ ,  $-NHCOCH_3$ , -CHO,  $-COOR^4$ ,  $-N_3$ ,  $-COR^3$ ,  $-R^3OH$ ,  $-R^3NHCOCH_3$ ,  $-R^3OSO_3R^4$ ,  $-R^3SO_3R^4$ ,  $-OR^3$ ,  $-SR^3$  and  $-R^3$ , wherein  $-R^3$  is p-nitrophenyl,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl, or  $C_2$ - $C_6$  alkynyl, if at the distal end of the substituent, or  $C_1$ - $C_6$  alkylene,  $C_2$ - $C_6$  alkenylene, or  $C_2$ - $C_6$  alkynylene, if at the proximal end of the substituent, and wherein  $R^4$  is H or a pharmaceutically acceptable cation.

Please cancel claims 1-27 and 40 without prejudice or disclaimer.

#### REMARKS

Claims 1-40 are pending in this application. Claims 1-27 and 40 have been withdrawn from consideration as being drawn to a non-elected invention. Claims 28-39 are rejected. By